Ashley Laranjo, PA
Physician Assistant · Plymouth, MANPI 1831668243
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Dexcom, Inc. accounts for 69.9% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $9,954, more than ten times the $158 reported in 2023. Among physician assistant clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $79.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$8K
- Corcept Therapeutics$600
- Amgen$568
- Novo Nordisk$385
- Xeris Pharmaceuticals, Inc.$224
- Kyowa Kirin, Inc.$202
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$5,92054%
- Travel & lodging$1,52014%
- Food & beverage$3,57232%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 14 | $7,698 |
| Corcept Therapeutics | 10 | $600 |
| Amgen | 22 | $568 |
| Novo Nordisk | 17 | $385 |
| Xeris Pharmaceuticals, Inc. | 10 | $224 |
| Kyowa Kirin, Inc. | 4 | $202 |
| Bayer | 11 | $195 |
| Medtronic | 6 | $166 |
| Lilly USA, LLC | 6 | $144 |
| Boehringer Ingelheim | 4 | $89 |
| Esperion Therapeutics, Inc. | 5 | $87 |
| Mannkind Corporation | 3 | $77 |
| Amneal Pharmaceuticals LLC | 3 | $70 |
| Tandem Diabetes Care, Inc. | 4 | $60 |
| AstraZeneca(2 entities) | 2 | $57 |
| Ascendis Pharma Endocrinology Inc | 2 | $52 |
| Novartis | 3 | $46 |
| Sequel Med Tech, LLC | 2 | $45 |
| Recordati_rare_diseases_inc. | 1 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $27 |
| GSK | 1 | $26 |
| Insulet Corporation | 1 | $26 |
| RGH Enterprises LLC | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Tolmar, Inc. | 1 | $24 |
| AbbVie | 1 | $19 |
| Chiesi USA, Inc. | 1 | $19 |
| BETA Bionics, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$7,410
- DEXCOM STELO GLUCOSE BIOSENSOR$7,410
- Korlym$429
- CRYSVITA$140
- EVENITY$125
How this compares
$11,013 in reported general payments places this provider in the 95th percentile of 3,507 physician assistant providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $55,155 |
| TrulicityDulaglutide | 24 | $31,764 |
| JardianceEmpagliflozin | 26 | $25,826 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $4,412 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 27 | $2,486 |
| Levothyroxine Sodium | 41 | $320 |
| Metformin Hcl ErMetformin Hcl | 18 | $254 |
| Metformin Hcl | 16 | $222 |
| Atorvastatin Calcium | 12 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $385 | $55,15539 claims |
| Lilly USA, LLCTrulicity | $144 | $31,76424 claims |
| Boehringer IngelheimJardiance | $89 | $25,82626 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $70 | $32041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,507 physician assistant providers in Massachusetts.
Other physician assistant in Plymouth
- Damon CurtisPlymouth$10K
- Vanessa RandoPlymouth$10K
- Elizabeth McLeishPlymouth$10K
- Rosemary ReardonPlymouth$10K
- Nghia TranPlymouth$8K
- Christopher MasseyWilbraham$190K
- Lizabeth O ConnorEverett$182K
- Kimberly ComeauSwampscott$120K
- Stacey PanasciSpringfield$113K
- Jason RandWaltham$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.